Minerva Neurosciences, Inc. Increase (Decrease) in Regulatory Liabilities
Minerva Neurosciences, Inc. (NERV) reported Increase (Decrease) in Regulatory Liabilities of $3.12 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRegulatoryLiabilities · last filed 2025-02-25
- Minerva Neurosciences, Inc. increase (decrease) in regulatory liabilities for the quarter ending 2023-12-31 was $0.00.
- Minerva Neurosciences, Inc. increase (decrease) in regulatory liabilities for the quarter ending 2023-09-30 was $0.00.
- Minerva Neurosciences, Inc. increase (decrease) in regulatory liabilities for the quarter ending 2023-06-30 was $0.00.
- Minerva Neurosciences, Inc. increase (decrease) in regulatory liabilities for the quarter ending 2023-03-31 was $3.12M.
- Minerva Neurosciences, Inc. increase (decrease) in regulatory liabilities for fiscal 2023 was $3.12M.
- Minerva Neurosciences, Inc. increase (decrease) in regulatory liabilities for fiscal 2022 was -$3.12M.
| Period end | Increase (Decrease) in Regulatory Liabilities 3 month | Increase (Decrease) in Regulatory Liabilities 6 month | Increase (Decrease) in Regulatory Liabilities 9 month | Increase (Decrease) in Regulatory Liabilities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $0.00 derived: sum of 3 quarters · filed 2025-02-25 | $3.12M 10-K · filed 2025-02-25 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $3.12M 10-Q · filed 2024-11-05 | $3.12M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $3.12M 10-Q · filed 2024-08-06 | $3.12M derived: sum of 3 quarters · filed 2024-08-06 | |
| 2023-03-31 | $3.12M 10-Q · filed 2024-05-01 | $3.12M derived: sum of 2 quarters · filed 2024-05-01 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$3.12M 10-K · filed 2024-02-22 | ||
| 2022-09-30 | -$3.12M 10-Q · filed 2023-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |